![](https://www.biopharma-reporter.com/var/wrbm_gb_food_pharma/storage/images/publications/pharmaceutical-science/biopharma-reporter.com/article/2024/06/20/fda-approves-biotest-s-yimmugo/17517916-1-eng-GB/FDA-approves-Biotest-s-Yimmugo.jpg)
FDA approves Biotest’s plasma-derived treatment for immunodeficiencies from BioPharma-Reporter.com
Yimmugo, an intravenous immunoglobulin therapeutic, is the first therapy developed by Biotest to be approved in the US. The treatment has previously been approved in the UK, Germany, and Austria. Following FDA approval, Biotest is planning the commercial …